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Abstract 
 
Aim: To compare the sensitivity, specificity and accuracy of the 2010 and 2017 revisions of the 
McDonald criteria in a Croatian cohort of patients with a clinically isolated syndrome (CIS). 
Methods: Prospectively collected data from 113 patients were retrospectively analyzed. 
Sensitivity, specificity and accuracy for both criteria were calculated regarding conversion to 
clinically definite multiple sclerosis (Poser CDMS) or multiple sclerosis (MS) (defined as 
fulfilment of clinical or MRI evidence for dissemination in space and the development of a 
second relapse and/or ≥ 1 new T2 lesions on the follow-up MRIs) during a two-year follow-up. 
Survival analysis was performed to estimate the cumulative risk of patients developing Poser 
CDMS. Binary logistic regression model was used to determine which variables are statistically 
significant predictors for the conversion to MS.  
Results: The 2017 revision had higher sensitivity (85 vs. 30% and 85 vs. 41%) and lower 
specificity (33 vs. 63% and 63 vs. 85%) compared to the 2010 revisions, for conversion to Poser 
CDMS and MS, respectively. Patients who did not meet the 2017 McDonald criteria had a 
higher chance of conversion-free survival for Poser CDMS than those who met the 2017 
McDonald criteria (p=0.037). Results of the multivariate regression analysis revealed that 
patients who at baseline fulfilled 2017 revisions of the McDonald criteria have the increased 
likelihood of conversion to MS (Exp(B) 9.68, 95%CI 3.62 – 25.90, p<0.00001). 
Conclusion: This study provides new information about the application of the 2017 revisions 
of the McDonald criteria in a Croatian cohort of patients with typical CIS. 
 
Key words: multiple sclerosis, McDonald criteria, dissemination in time, dissemination in 
space, CSF-specific oligoclonal IgG bands, symptomatic lesions 
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Highlights 
 During the 2-year follow-up, the 2017 revision had higher sensitivity and lower 
specificity compared to the 2010 revisions, for conversion to Poser CDMS and MS, 
respectively.  
 During the 2-year follow-up, patients who did not meet the 2017 McDonald criteria 
had a higher chance of conversion-free survival for Poser CDMS than those who met 
the 2017 McDonald criteria.  
 During the 2-year follow-up, patients who at baseline fulfilled 2017 revisions of the 
McDonald criteria have the increased likelihood of conversion to MS.  
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Introduction 
 
Multiple sclerosis (MS) is a chronic, demyelinating, immune-mediated disorder of the central 
nervous system with progressive neuroaxonal degeneration (1). Although significant advances 
in the diagnosis and treatment of MS have been made, there is still a considerable delay 
between the onset of MS-characteristic symptoms and establishing the diagnosis and treating 
MS (2). The delay in the diagnosis and treatment can have devastating consequences on a 
person with MS (pwMS), as substantial evidence exists arguing that early treatment is more 
effective than treatment later in the disease course (3,4). 
Over the years there have been several attempts to modify the criteria in order to establish 
the diagnosis of MS earlier and more easily (5, 6,7,8,9). Compared to the 2010 revisions, 
following changes have been made in in the recently published 2017 revisions to the 
McDonald criteria: 1) Cortical and juxtacortical lesions can be used in fulfilling MRI criteria for 
dissemination in space (DIS); 2) Symptomatic and asymptomatic MRI lesions can be 
considered in the determination of DIS or dissemination in time (DIT), and 3) In a patient with 
a typical CIS and fulfilment of DIS criteria, presence of CSF-specific IgG oligoclonal bands allows 
a diagnosis of MS (9). 
As for any newly developed criteria, appropriate use and performance of the criteria across 
patient populations are essential. Therefore, the aim of this study was to compare the 
sensitivity, specificity, predictive value and accuracy of the 2010 and 2017 revisions of the 
McDonald criteria in a Croatian cohort of patients with a CIS, in order to evaluate the 
performance of the aforementioned criteria in the diagnosis of MS. 
 
Methods 
 
Patients 
Patients were recruited from the database of BACIS project (10) in which consecutive patients 
with CIS were recruited into a two-year prospective clinical and neurophysiological follow-up 
from October 2014 until April 2016. All patients signed informed consent and the study was 
approved by Ethical Committees of the University Hospital Center Zagreb and the University 
of Zagreb, School of Medicine. 
 
Baseline variables 
For the purpose of the present study, data from all 128 patients participating in BACIS project 
were analyzed and only patients with available following data were included: definite 
diagnosis of CIS, a complete neurological examination, CSF analysis for the presence of CSF-
specific oligoclonal IgG bands, visual evoked potentials, a baseline brain MRI obtained less 
than 3 months from the clinical onset, at least 1 follow-up brain MRI obtained in the second 
year of follow-up, completed two-year follow-up. Additionally, baseline cervical spinal cord 
MRI was analyzed when available. 
A CIS is defined as an acute or subacute episode of neurological dysfunction due to 
inflammatory demyelination that lasts more than 24 hours and occurs in the absence of fever, 
infection or encephalopathy (11). CIS episodes were further divided into optic neuritis, 
transverse myelitis, brainstem/cerebellar syndromes, hemispheral syndromes (hemiparesis or 
homonymous hemianopia) and multifocal presentations. The presence of CSF-specific 
oligoclonal IgG bands was detected using isoelectric focusing and immunofixation. All the 
baseline brain MRIs were performed on 1.5 T scanners. Axial T2-weighted, fluid-attenuated 
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inversion recovery (FLAIR), and post-gadolinium T1-weighted sequences with 5 mm images 
were analyzed for the presence of lesions. Axial T2 cervical spinal cord sequence was analyzed 
only during the baseline visit, if available. 
Baseline scans were scored for DIS and DIT according to the revised McDonald criteria from 
2010 and 2017 (Table 2). Following this, we determined for each patient whether they met 
the criteria for the diagnosis of MS according to the revised McDonald criteria from 2010 and 
2017, while taking into account clinical, MRI and CSF data.  
 
Two-year follow-up variables 
Two sets of analyses were performed to compare the 2010 and 2017 McDonald criteria.  
The first analysis took into account patients who converted to MS during a two-year follow-
up. Conversion to MS was defined if the patient who fulfilled clinical or MRI evidence for DIS, 
during the two-year follow-up fulfilled DIT, which was defined as the presence of one or both 
of the following parameters (3):  
1. the patient developed a second relapse 
2. ≥ 1 new T2 lesions on any of the follow-up MRIs 
If an individual had a second relapse in the form of optic neuritis or transverse myelitis, a 
relevant MRI scan was not available, therefore a difference between clinical and MRI results 
was present.  
The second analysis took into account only those patients who converted to clinically definite 
multiple sclerosis (Poser CDMS) according to the Poser criteria (i.e. experienced a second 
relapse) during the two-year follow-up, regardless of MRI findings. 
For both analyses the MS relapse was defined as an occurrence of new or worsening 
neurological symptoms attributable to MS that met the following criteria: symptoms must 
persist for >24 hours and should not be attributable to confounding clinical factors (e.g. fever, 
infection, injury, adverse reactions to medications), symptoms should be preceded by 
neurological stability for at least 30 days, symptoms should be accompanied by new objective 
neurological worsening determined with EDSS/Functional Systems Score (FSS) assessment.  
All follow-up MRIs were performed on 1.5 T scanners with the same sequences analyzed and 
compared with the baseline scans. 
For both analysis, all patients who fulfilled either 2010 or 2017 criterion at baseline were 
considered as positive cases for that specific criterion and patients not meeting that criterion 
were considered as negative cases.  
Patients who converted to MS or Poser CDMS and fulfilled 2010 or 2017 criteria were 
considered as true positive (TP). Patients who did not convert to MS or Poser CDMS and did 
not fulfill 2010 or 2017 criteria were considered as true negative (TN). Patients who converted 
to MS or Poser CDMS but did not fulfill 2010 or 2017 criteria were considered as false negative 
(FN). Patients who did not convert to MS or Poser CDMS but fulfilled 2010 or 2017 criteria 
were considered as false positive (FP). The sensitivity, specificity, positive predictive value 
(PPV), negative predictive value (NPV) and accuracy of the two versions of the McDonald’s 
criteria were determined, separately for each analysis. 
 
Primary outcomes 
The primary outcomes were to determine sensitivity, specificity, predictive value and accuracy 
of the 2010 and 2017 revisions of the McDonald criteria and to compare the performance of 
both criteria in the diagnosis of MS. 
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Secondary outcomes 
Secondary outcomes were to estimate the cumulative risk and hazard ratio of patients 
developing Poser CDMS using the 2010 and 2017 McDonald criteria during a two-year follow-
up. 
Furthermore, in order to examine the influence of the sex, age and 2010 or 2017 revisions to 
the McDonald criteria on the likelihood that patients will develop conversion to MS, a 
multivariate logistic regression model was used. 
 
Statistical analysis 
McNemar test was used to determine if there is a difference in dichotomous dependent 
variables (2010 McDonald criteria and 2017 McDonald criteria, McDonald criteria and 
frequency of conversion to MS/Poser CDMS). Survival analysis was performed in the form of 
Kaplan-Meier curves in order to estimate the cumulative risk of patients developing Poser 
CDMS, and in the form of the Cox regression model with the time to conversion to Poser CDMS 
as an outcome, in order to obtain hazard ratio (HR) adjusted for sex and age, for different 
versions of McDonald criteria. 
Binary logistic regression model was used to determine which variables (sex, age, 2010 
McDonald criteria or 2017 McDonald criteria) are statistically significant predictors for the 
conversion to MS.  
Statistical analysis was performed using the IBM SPSS software, version 20. Two-tailed p 
values <0.05 were considered as statistically significant. 
 
 
  
Results 
 
Patients, baseline, and two-year follow-up variables 
Altogether 113 patients with complete data were available for the analysis. Baseline patient 
characteristics are presented in Table 1. At the baseline visit, 39 (35%) and 83(74%) fulfilled 
the 2010 and 2017 revision of the McDonald criteria, respectively. Out of 44 patients who did 
not fulfill the 2010, but fulfilled the 2017 revision of the McDonald’s criteria, 43 (98%) fulfilled 
the 2017 revision because of the presence of CSF-specific oligoclonal IgG bands, 6 (14%) 
because of the presence of symptomatic brainstem lesions and 9 (20%) because of the 
presence of symptomatic cervical spinal cord lesions (one patient could fulfill the 2017 revision 
of the McDonald’s criteria due to more than 1 criteria). 
None of the patients received disease modifying therapy until the occurrence of the second 
relapse. During the two-year follow up, 73 (65%) developed ≥1 new T2 lesion on one of the 
follow-up MRIs, while 40 (35%) developed a new relapse. Conversion to MS occurred in 86 
(76%) and in Poser CDMS in 40 (35%) patients.  
 
Primary outcomes 
Sensitivity, specificity, predictive value and accuracy of the 2010 and 2017 revisions of the 
McDonald criteria for conversion to MS and Poser CDMS are presented in Table 3.   
In order to compare the criteria, we used the McNemar test and all results are presented in 
Table 4. At the baseline visit, significantly more patients fulfilled 2017 revisions of the 
McDonald criteria than 2010 revisions of the McDonald criteria (83 vs. 39, p<0.001). A 
significant proportion of patients who converted to MS during the two-year follow-up (51 
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patients, 59% of all patients that converted to MS), did not fulfill 2010 revisions to the 
McDonald criteria at baseline (p<0.001). Only 31% (12 out of 39) patients who fulfilled 2010 
revisions of the McDonald criteria did convert to Poser CDMS, but 62% (46 out of 74) patients 
who did not fulfill the 2010 criteria, also did not convert to Poser CDMS. Most of the patients 
who fulfilled 2017 revisions to the McDonald criteria at baseline converted to MS (88%, 73 out 
of 83). However, only 41% (34 out of 83) patients who fulfilled 2017 revisions to the McDonald 
criteria at baseline converted to Poser CDMS. 
 
Secondary outcomes 
Kaplan-Meier curves used to estimate the cumulative risk of patients developing Poser CDMS 
using the 2010 and 2017 McDonald criteria are shown in Figure 1. Patients who did not meet 
the 2017 McDonald criteria had a higher chance of conversion-free survival than those who 
met the 2017 McDonald criteria (figure 1, p=0.037), while for 2010 McDonald criteria there 
was no statistically significant difference in the survival distribution between two conditions. 
Results of the Cox regression analysis showed that adjusted hazard ratios for 2010 revisions 
to the McDonald criteria (HR=0.814, p=0.552) and 2017 revisions to the McDonald criteria 
(HR=2.333, p=0.056) were not statistically significant. Also, hazard ratios for sex and age were 
not statistically significant (all p values > 0.05). 
The multivariate logistic regression model for the 2010 criteria was not statistically significant 
χ2(3) = 6.931, p=0.074. On the other hand, the multivariate logistic regression model for the 
2017 criteria was statistically significant, χ2(3) = 22.276, p<0.0001 and it correctly classified 
79.6% of cases. Results of the multivariate regression analysis revealed that patients who at 
baseline fulfilled 2017 revisions of the McDonald criteria have the increased likelihood of 
conversion to MS (Exp(B) 9.68, 95%CI 3.62 – 25.90, p<0.00001), while sex and age were not 
statistically significant predictors (p=0.832 and p=0.784). 
 
Discussion 
 
In this study we evaluated the performance of the 2010 and 2017 McDonald criteria in a 
cohort of patients who had a typical CIS in terms of Poser CDMS conversion at 2 years. We 
have found that both criteria had similar accuracy, with 2010 McDonald criteria having low 
sensitivity and moderate specificity, and 2017 McDonald criteria having high sensitivity and 
low specificity.  
When we compared the 2010 and 2017 revisions of the McDonald criteria relating to the 
conversion to MS, a significant proportion of patients who converted to MS during the two-
year follow-up, did not fulfill 2010 revisions to the McDonald criteria at baseline. Opposite to 
this, most of the patients who fulfilled 2017 revisions to the McDonald criteria at baseline 
converted to MS. Contrary, no difference was observed related to conversion to Poser CDMS.  
Similar to our observation, no difference was observed in previous studies when comparing 
the 2005 and 2010 revisions of the McDonalds criteria (12,13). It has to be emphasized that 
these differences depend on the duration of the follow-up, with longer follow-up yielding 
better congruence of the criteria (13). Furthermore, diagnosis of MS could be made in 
significantly higher number of patients and significantly faster with the 2017 criteria compared 
to 2010 criteria. The main reason for this is the inclusion of CSF-specific oligoclonal IgG bands 
in the 2017 revisions of the McDonald criteria, to substitute for the requirement of fulfilling 
DIT. Several studies have emphasized the importance of CSF-specific oligoclonal IgG bands in 
patients with CIS, with the evidence that the risk of conversion to MS substantially increases 
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if CSF-specific oligoclonal IgG bands are present at baseline (14,15). Another important factor 
in the 2017 revisions of the McDonald criteria is presence of symptomatic brainstem and 
spinal cord lesions. In our cohort, 6 patients did not meet 2010 revisions of the McDonald 
criteria because of presence of symptomatic brainstem and 9 because of presence of 
symptomatic spinal cord lesion. The 2017 revisions of the McDonald criteria no longer 
distinguish between symptomatic and asymptomatic lesions based on several studies showing 
that including lesions in the symptomatic region in DIS increases the sensitivity of MRI criteria 
for diagnosing MS without compromising specificity. (16,17) 
Survival probability analyses showed that only patients who did not meet the 2017 McDonald 
criteria had a higher chance of conversion-free survival to Poser CDMS than those who met 
the 2017 McDonald criteria. In a recently published study comparing 2010 revisions of the 
McDonald criteria and the 2016 MAGNIMS criteria, patient not meeting both criteria had a 
higher chance of conversion-free survival (18). Furthermore, this study also showed that both 
sets of criteria according to adjusted hazard ratio, carried a significantly increased risk for 
conversion to Poser CDMS, while in our studies the risk was higher only for 2017 revisions of 
the McDonald criteria, although not statistically significant. This discrepancy could be 
explained with longer follow-up in the former study. However, when we performed 
multivariate logistic regression analysis, patients with CIS who fulfilled the 2017 revision of 
the McDonald criteria, had the increased likelihood of conversion to MS. 
The main limitations of our study are small number of subjects, the short follow-up period and 
a retrospective design. However, we examined patients regularly every six-months in a 
prospective manner, with only 12% of the patients excluded from the analysis (either for 
alternate diagnosis or because they were lost to follow-up). Furthermore, there is a possibility 
of selection bias, because all patients were followed in a tertiary medical center. However, 
this is unlikely due to the organization of the neurology service in Croatia, where more than 
60% of all pwMS in Croatia are being followed and more than 50% are receiving disease 
modifying therapy in our center. This argues that the obtain results may be applied to patients 
usually seen in clinical practice in Croatia or elsewhere in Europe. Thirdly, due to the MRI 
availability, MRI scans were acquired using different parameters (eg, slice thickness), but like 
previously reported, this approach allows to evaluate the MRI criteria in a situation close to a 
clinical setting (18). 
In conclusion, this study provides new information about the application of the 2017 revisions 
of the McDonald criteria in a Croatian cohort of patients with typical CIS. While, we found no 
difference in the accuracy between 2010 and 2017 revisions related to conversion to Poser 
CDMS, the 2017 revisions of the McDonald criteria had higher accuracy when looking 
conversion to MS including MRI findings, allowing making the diagnosis of MS in a significant 
proportion of patients with CIS during the 2-year follow-up. These findings may assist in 
treatment decisions, as identification of patients with a higher probability of conversion to MS 
is associated with different treatment approaches compared to patients with lower 
probability of conversion. 
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Table 1. Baseline characteristics 
 Patients with CIS (N=113) 
Demographic   
Age at onset 32.1±8.7 
Sex  
Male  80 (70.8%) 
Female 33 (29.2%) 
Clinical   
EDSS at baseline 1.0 (0-3.5) 
Type of CIS  
  Monofocal 109 (96.5%) 
Optic Neuritis 34 (30.1%) 
Incomplete transverse myelitis 36 (31.9%) 
Brainstem/cerebellar 27 (23.9%) 
Hemispheral 12 (10.6%) 
  Multifocal 4 (3.5%) 
Presence of oligoclonal IgG bands 94 (83.2%) 
Meeting 2017 McDonald criteria because of 
oligoclonal IgG bands 
43 (38.1%) 
Neurophysiological   
Prolonged VEP latencies on the right eye 3 (2.7%) 
Prolonged VEP latencies on the left eye 21 (18.6%) 
MRI  
Presence of lesions 110 (97.3%) 
Number of lesions 11 (0-76) 
Presence of gadolinium-enhancing lesions 43 (38.1%) 
Cervical spinal cord MRI available 85 (75%) 
Presence of cervical spinal cord lesions (% of 
available MR scans) 
48 (56%) 
Not meeting 2010 McDonald criteria 
because of presence of symptomatic 
brainstem lesion  
6 (5.3%) 
Not meeting 2010 McDonald criteria 
because of presence of symptomatic spinal 
cord lesion 
9 (8%) 
 
EDSS – expanded disability status scale, CIS – clinically isolated syndrome, VEP – visual evoked 
potentials 
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Table 2. Differences in MRI dissemination in space and dissemination in time criteria between 
2010 and 2017 McDonald’s criteria. 
 2010 McDonald’s criteria 2017 McDonald’s criteria 
Dissemination is space ≥1 T2 lesion in at least 2 of 4 
area of CNS: 
periventricular 
juxtacortical 
infratentorial* 
spinal cord* 
≥1 T2 lesion in at least 2 of 4 
area of CNS: 
periventricular 
cortical/juxtacortical 
infratentorial 
spinal cord 
Dissemination in time Simultaneous presence of 
asymptomatic gadolinium-
enhancing and 
nonenhancing lesions. 
Simultaneous presence of 
gadolinium-enhancing and 
nonenhancing lesions.  
*In a subject with brainstem or spinal cord type of CIS, the symptomatic lesion is excluded 
from the count. 
 
 
Table 3. Sensitivity, specificity, predictive value and accuracy of the 2010 and 2017 revisions 
to the McDonald criteria. 
Conversion to MS 
 TP FP TN FN Sensitivity (95% 
CI) 
Specificity (95% 
CI) 
PPV (95% CI) NPV (95% CI) Accuracy (95% 
CI) 
2010 35 4 23 51 0.41 (0.30-0.52) 0.85 (0.66-0.96) 0.90 (0.77-0.96) 0.31 (0.26-0.36) 0.51 (0.42-0.61) 
2017 73 10 17 13 0.85 (0.76-0.92) 0.63 (0.42-0.81) 0.88 (0.82-0.92) 0.57 (0.42-0.70) 0.80 (0.71-0.87) 
Conversion to Poser CDMS 
2010 12 27 46 28 0.30 (0.17-0.47) 0.63 (0.51-0.74) 0.31 (0.20-0.44) 0.62 (0.56-0.68) 0.51 (0.42-0.61) 
2017 
 
34 49 24 6 0.85 (0.70-0.94) 0.33 (0.22-0.45) 0.41 (0.36-0.46) 0.80 (0.64-0.90) 0.51 (0.42-0.61) 
MS – multiple sclerosis, CDMS – clinically definitive multiple sclerosis, TP – true positive, TN – 
true negative, FP – false positive, FN – false negative 
Sensitivity = TP/(TP+FN) 
Specificity = TN/(TN+FP) 
PPV (positive predictive value) = TP/(TP+FP) 
NPV (negative predictive value) = TN/(TN+FN) 
Accuracy = (TP+TN)/(TP+FP+TN+FN) 
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Table 4. Comparison between 2010 and 2017 revisions of the McDonald criteria using the 
McNemar test. 
 Negative Positive P value 
McDonald 2017  
McDonald 2010 Negative 30 44 <0.001 
Positive 0 39 
 Conversion to MS  
McDonald 2010 Negative 23 51 <0.001 
Positive 4 35 
 Conversion to MS  
McDonald 2017 Negative 17 13 0.678 
Positive 10 73 
 Conversion to Poser CDMS  
McDonald 2010 Negative 46 28 1.000 
Positive 27 12 
 Conversion to Poser CDMS  
McDonald 2017 Negative 24 6 <0.001 
Positive 49 34 
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Figures 
 
Figure 1. Kaplan-Meier curves showing the survival probability estimates of not developing 
clinically definite multiple sclerosis two years from disease onset considering 2010 and 2017 
McDonald criteria.  
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